An integrated analysis of 2 phase 3 studies with up to 6.5 years of follow-up reported the outcomes of first-line ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and high-risk genomic features.
Jan A. Burger, MD, PhD
Advertisement
Articles by Jan A. Burger, MD, PhD
The leukemia expert discussed exciting research being presented at this year’s ASH Annual Meeting.
Advertisement
Latest Updated Articles
Jan A. Burger, MD, PhD, on Long-Term Outcomes with Ibrutinib in High-Risk Patients with CLL/SLLPublished: December 7th 2020 | Updated:
Jan A. Burger, MD, PhD, on CLL Research Coming Out of ASHPublished: December 6th 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
2
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
3
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
4
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
5
